Our Approach

our approach

Our advisory work starts from a position of respect
for our clients' organization, people,
products and science.

OUR RELATIONSHIPS

our approach

We have devoted our careers to the life
sciences industry and have the deepest respect
and admiration for the participants in it.

OUR TRACK RECORD

our approach

We are a very active advisor in the market.
Torreya Partners has successfully closed over
100 assignments since our founding in 2007.

Our Perspective

our approach

We often take an operating perspective
to strategic and transaction work.

PhosImmune

Sale to Agenus

$10 million upfront in cash & stock + up to $35 million in milestones

December 2015

North America

VistaPharm

Sale to Vertice Pharma (backed by Warburg Pincus)

November 2015

North America

XOMA

Sale of Biologics Manufacturing Facilities to Agenus

$5 million in cash and $1 million in Agenus stock

November 2015

North America

November 11-16, 2015

American Society of Nephrology
Renal Week

Philadelphia, PA

November 19-20, 2015

Jefferies Healthcare Conference

London, England

December 1-2, 2015

Life Sciences Summit

New York, NY

December 23, 2015

Agenus Acquires PhosImmune with a Novel Class of Cancer Neoantigens

MORE

November 17, 2015

Pharma Industry Veterans Launch Vertice Pharma in Partnership with Warburg Pincus; Announce Acquisition of VistaPharm

MORE

November 5, 2015

XOMA Announces the Sale of Its Manufacturing Facilities to Agenus

MORE